Dr. Marina Holz, associate professor of biology at Yeshiva University's Stern College for Women, recently published an article in Cell Cycle. Titled "Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells," the article demonstrates how the combination of Rapamycin, an FDA-approved drug, with a natural agent, Resveratrol, is effecting in killing cells with a mutation in the TSC2 gene that causes abnormalities associated with lymphangioleiomyomatosis (LAM), a rare disease affecting women of childbearing age which causes cystic lung destruction. Holz's research was sponsored mainly by the LAM Foundation, but also by the National Institutes of Health and the American Cancer Society, with generous support from the Atol Foundation. Three of the researchers involved in the study are Stern College graduates: Dr. Anya Alayev graduated from Stern College as well as YU's Albert Einstein College of Medicine and is a recipient of a fellowship from the National Cancer Center, and Rose Snyder and Sara Malka Berger are members of the classes of '12 and '13, respectively.